Icon
+91 94997 68112
Login Register

EPCLUSA - (400MG;100MG, 200MG;50MG ; Tablet)

SOFOSBUVIR; VELPATASVIR Gilead
400MG;100MG, 200MG;50MG ; Tablet
Less Than $1000 mn
None None
Less Than 5
 None
None None
EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection: • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin.
Yes
EPCLUSA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14 Patent 15
*** *********
********** *************** ******** ********** *************** ******** ********** *************** ******** ********** *************** ******** ********** *************** ******** ********** **************** ************ *** ******* *** ******** ********* * ***** ********** **************** ********** **************** ********* ********* ********* ********* ********* ********* *********** *********** ** *** ********* ********* *********** *********** ** *** ********* ********* *********** *********** ** *** ********* *********

EPCLUSA - (150MG;37.5MG, 200MG;50MG ; PELLETS)

SOFOSBUVIR; VELPATASVIR Astrazeneca
150MG;37.5MG, 200MG;50MG ; PELLETS
Less Than $1000 mn
None None
Less Than 5
 None
None None
EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adults and pediatric patients 3 years of age and older with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection: • without cirrhosis or with compensated cirrhosis • with decompensated cirrhosis for use in combination with ribavirin.
Yes
EPCLUSA Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12 Patent 13 Patent 14
*** *********
********** *************** ******** ********** *************** ******** ********** *************** ******** ********** *************** ******** ********** *************** ******** ********** **************** ************ *** ******* *** ******** ********* * ***** ********** **************** ********** **************** ********* ********* ********* ********* ********* ********* *********** *********** ** *** ********* ********* *********** *********** ** *** ********* *********

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Drug Name Generic Name Dosage Route of Administration Probable FTF Known Para IV Filers Other ANDA Developers

Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.   Privacy Policy.   Terms and Conditions.